trending Market Intelligence /marketintelligence/en/news-insights/trending/0n4s7zydf_xd5t5_grxysq2 content esgSubNav
In This List

FDA sets target date for Shield Therapeutics' iron deficiency drug application

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


FDA sets target date for Shield Therapeutics' iron deficiency drug application

Shield Therapeutics PLC said the U.S. Food and Drug Administration set July 27, 2019, as the target action date for its new drug application for Feraccru.

Feraccru is a treatment for iron deficiency already approved in the EU and Switzerland. The medicine is a non-salt, oral formulation of ferric iron, seen as a safer alternative to intravenous iron therapy.

U.K.-based Shield Therapeutics develops hospital-focused pharmaceuticals for unmet medical needs.